Form 4: Bausch + Lomb Director John Paulson Receives Annual Equity Grant

Bausch + Lomb Corporation (BLCO) Director and 10% Owner John Paulson has reported the acquisition of 20,338 common shares through an annual Restricted Share Unit (RSU) grant, aligning his interests with shareholders.

Summary

• John Paulson, a Director and 10% Owner of Bausch + Lomb Corporation (BLCO), acquired 20,338 common shares.
• The acquisition occurred on May 27, 2025, and was reported via a Form 4 filing with the SEC.
• The shares were acquired at a price of $0, indicating they were part of an equity grant rather than a purchase.
• This transaction reflects an annual grant of Restricted Share Units (RSUs) to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
• Following this transaction, John Paulson beneficially owns 69,965 common shares directly.
• The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU grant aligns the director's interests with shareholders, which is generally viewed favorably. It is a routine transaction and does not indicate any significant operational or financial changes.

Positives

• The grant of Restricted Share Units (RSUs) to Director John Paulson aligns his interests with those of the company's shareholders, as the value of his compensation is tied to the company's stock performance.
• The transaction is part of a pre-existing, approved compensation plan (Bausch + Lomb Corporation 2022 Omnibus Incentive Plan), indicating structured corporate governance regarding director remuneration.

Future Outlook

The granted Restricted Share Units (RSUs) are scheduled to vest immediately prior to the next annual meeting of shareholders, at which point they will settle into common shares of Bausch + Lomb Corporation.

Industry Context

The practice of granting equity, such as Restricted Share Units (RSUs), to non-employee directors is a common and widely accepted form of compensation across various industries, including the healthcare and pharmaceutical sectors. It is designed to incentivize long-term commitment and align the interests of directors with those of the company's shareholders.

Comparison to Industry Standards

• Equity compensation for non-employee directors, often in the form of RSUs or stock options, is a standard practice among publicly traded companies globally, including peers in the healthcare and vision care industry such as Alcon, CooperCompanies, and Johnson & Johnson (through its vision care segment).
• The Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, under which these RSUs were granted, is typical of broad-based incentive plans used by large corporations to attract and retain talent and align management/director incentives with shareholder value creation.
• The vesting schedule, tied to the next annual meeting, is a common approach for annual director grants, ensuring continued service through the fiscal year.

Corporate Governance

Related Party Transactions

• The acquisition of 20,338 common shares by John Paulson, a Director and 10% Owner, constitutes a related party transaction as it involves an equity grant from the company to an insider.

Stakeholder Impact

• Shareholders: The RSU grant aligns the interests of Director John Paulson with shareholders, as his compensation is tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: No direct impact on employees is indicated by this specific filing, though the Omnibus Incentive Plan may also cover employee equity grants.

Next Steps

• The granted Restricted Share Units (RSUs) are scheduled to vest immediately prior to the next annual meeting of shareholders.

Key Dates

Keywords

Bausch + Lomb, BLCO, John Paulson, Form 4, Insider Transaction, Restricted Share Units, RSU, Equity Grant, Director Compensation, Beneficial Ownership, SEC Filing